K
Kyriakos P. Papadopoulos
Researcher at University of Texas Health Science Center at San Antonio
Publications - 330
Citations - 11771
Kyriakos P. Papadopoulos is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 47, co-authored 274 publications receiving 8985 citations. Previous affiliations of Kyriakos P. Papadopoulos include University of Maryland, Baltimore & University of Washington.
Papers
More filters
Journal ArticleDOI
PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
Michael R. Migden,Danny Rischin,Chrysalyne D. Schmults,Alexander Guminski,Axel Hauschild,Karl D. Lewis,Christine H. Chung,Leonel Hernandez-Aya,Annette M. Lim,Anne Lynn S. Chang,Guilherme Rabinowits,Alesha A. Thai,Lara Dunn,Brett G.M. Hughes,Nikhil I. Khushalani,Badri Modi,Dirk Schadendorf,Bo Gao,Frank Seebach,Siyu Li,Jingjin Li,Melissa Mathias,Jocelyn Booth,Kosalai Kal Mohan,Elizabeth Stankevich,Hani M. Babiker,Irene Brana,Marta Gil-Martin,Jade Homsi,Melissa Lynne Johnson,Victor Moreno,Jiaxin Niu,Taofeek K. Owonikoko,Kyriakos P. Papadopoulos,George D. Yancopoulos,Israel Lowy,Matthew G. Fury +36 more
TL;DR: Among patients with advanced cutaneous squamous‐cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors.
Journal ArticleDOI
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients
Jill Hallin,Lars D. Engstrom,Lauren Hargis,Andrew Calinisan,Ruth Aranda,David Briere,Niranjan Sudhakar,Vickie Bowcut,Brian R. Baer,Joshua Ballard,Michael Burkard,Fell Jay Bradford,John P. Fischer,Guy Vigers,Yaohua Xue,Sole Gatto,Julio Fernandez-Banet,Adam Pavlicek,Karen Velastagui,Richard C. Chao,Jeremy Barton,Mariaelena Pierobon,Elisa Baldelli,Emanuel F. Patricoin,Douglas P. Cassidy,Matthew A. Marx,Igor I. Rybkin,Melissa Lynne Johnson,Sai-Hong Ignatius Ou,Piro Lito,Kyriakos P. Papadopoulos,Pasi A. Jänne,Peter Olson,James G. Christensen +33 more
TL;DR: Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant non-clinical models identified mechanisms implicated in limiting anti-tumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.
Journal ArticleDOI
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik,S. Peter Kang,Drew W. Rasco,Kyriakos P. Papadopoulos,Jeroen Elassaiss-Schaap,Muralidhar Beeram,Ronald Drengler,Cong Chen,Lon Smith,Guillermo Espino,Kevin Gergich,Liliana Delgado,Adil Daud,Jill A. Lindia,Xiaoyun Nicole Li,Robert H. Pierce,Jennifer H. Yearley,Dianna Wu,Omar F Laterza,Manfred Lehnert,Robert Iannone,Anthony W. Tolcher +21 more
TL;DR: Pembrolizumab was well tolerated and associated with durable antitumor activity in multiple solid tumors, and Mechanism-based translational models with a focus on intratumor exposure prediction suggested robust clinical activity would be observed at doses ≥2 mg/kg every 3 weeks.
Journal ArticleDOI
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik,Lee S. Rosen,Sara M. Tolaney,Anthony W. Tolcher,Jonathan W. Goldman,Leena Gandhi,Kyriakos P. Papadopoulos,Muralidhar Beeram,Drew W. Rasco,John Hilton,Aejaz Nasir,Richard P. Beckmann,Andrew E. Schade,Angie D. Fulford,Tuan S. Nguyen,Ricardo Martinez,Palaniappan Kulanthaivel,Lily Q. Li,Martin Frenzel,Damien M. Cronier,Edward M. Chan,Keith T. Flaherty,Patrick Y. Wen,Geoffrey I. Shapiro +23 more
TL;DR: Abemaciclib represents the first selective inhibitor of CDK4 and CDK6 with a safety profile allowing continuous dosing to achieve sustained target inhibition, and this first-in-human experience demonstrates single-agent activity for patients with advanced breast cancer, NSCLC, and other solid tumors.
Journal ArticleDOI
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap,Li Yan,Amita Patnaik,Ivy Fearen,David Olmos,Kyriakos P. Papadopoulos,Richard D. Baird,Liliana Delgado,Adekemi Taylor,Lisa Lupinacci,Ruth Riisnaes,Lorna Pope,Simon P. Heaton,George Thomas,Michelle D. Garrett,Daniel M. Sullivan,Johann S. de Bono,Anthony W. Tolcher +17 more
TL;DR: MK-2206 was well tolerated, with evidence of AKT signaling blockade, and Rational combination trials are ongoing to maximize clinical benefit with this therapeutic strategy.